Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1094887
Abstract: KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological… read more here.
Keywords: krasg12d inhibitors; krasg12d; potent noncovalent; noncovalent krasg12d ... See more keywords